OncoMed Pharma (OMED) Misses Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St futures rise ahead of jobs report as bond market steadies, oil slips
- U.S. economy adds 29,000 jobs in September
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- BofA's Hartnett sees risk-off mood lasting until dollar peaks
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
OncoMed Pharmaceuticals Reports Second Quarter 2016 Financial Results
August 9, 2016 4:07 PM EDTÂ OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported second quarter financial results. As of June 30, 2016, cash, cash equivalents and short-term investments totaled $171.5 million.Â
With seven OncoMed-discovered drugs in fourteen clinical trials, we enter the second half of this year following the presentation of encouraging data from across our pipeline at the AACR and ASCO annual meetings,... More
